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StatinsWe performed a focused siRNA screen in an A549 dengue type 2 New Guinea C subgenomic replicon cell line
(Rluc-replicon) that contains a Renilla luciferase cassette. We found that siRNA mediated knock down of
mevalonate diphospho decarboxylase (MVD) inhibited viral replication of the Rluc-replicon and DEN-2 NGC
live virus replication in A549 cells. When the Rluc-replicon A459 cells were grown in delipidated media the
replicon expression was suppressed and MVD knock down could further sensitize Renilla expression.
Hymeglusin and zaragozic acid A could inhibit DEN-2 NGC live virus replication in K562 cells, while
lovastatin could inhibit DEN-2 NGC live virus replication in human peripheral blood mononuclear cells.
Renilla expression could be rescued in ﬂuvastatin treated A549 Rluc-replicon cells after the addition of
mevalonate, and partially restored with geranylgeranyl pyrophosphate, or farnesyl pyrophosphate. Our data
suggest genetic and pharmacological modulation of cholesterol biosynthesis can regulate dengue virus
replication.
© 2009 Elsevier Inc. All rights reserved.IntroductionDengue is a mosquito borne viral infection found in tropical and
sub-tropical regions around the world. The World Heath Organization
(WHO) estimates there are as many as 50 million cases of dengue
infection worldwide and global warming provides a signiﬁcant
selective advantage for dengue infection spreading into new areas.
Being endemic in more than 100 countries, the risk of acquiring a
dengue infection poses a signiﬁcant healthcare threat to millions of
people around the world (Pupo-Antúnez et al., 1997; Gubler, 1997).
Dengue virus (DENV) is a member of the Flaviviridae family of
enveloped, positive-strand RNA viruses (Lindenbach and Rice, 2003).
There are four distinct serotypes of dengue virus, DENV1–4, and
transmission of the virus occurs via mosquito (most commonly Aedes
aegypti) bites (Lindenbach and Rice, 2003). DENV is unusual among
arboviruses in that it does not require an enzootic cycle and is
maintained by a human–mosquito–human cycle. The virus is com-
posed of three structural proteins, capsid (C), pre-membrane (prM),
envelope (E), and sevenviral non-structural proteins (NS1, 2a, 2b, 3, 4a,
4b, and 5) (Lindenbach and Rice, 2003). Since the structure of the virus
has been solved, binding of the viral E protein to a host receptor DC-cted at Novartis Institutes for
re, Cambridge, MA 02139, USA.
her).
ll rights reserved.SIGN has been postulated to be one possible route of viral entry into
host cells (Kuhn et al., 2002; Pokidysheva et al., 2006). Most dengue
virus infections result in dengue fever (DF) which is a self limiting
illness associated with fever, headache, myalgia (muscle pain),
arthralgia (joint pain), and thrombocytopaenia. Infection with one
serotype of dengue leads to a lifelong immunity to that serotype. Re-
infectionwith anyof the other three serotypeswithin sixmonths of the
ﬁrst infection leads to protective immunity. After sixmonths the host is
susceptible to a more severe form of the disease know as dengue
hemorrhagic fever (DHF), if infected with a different dengue serotype
(Rothman, 2004). DHF is associated with plasma leakage and bleeding
diathesis, which may progress into dengue shock syndrome (DSS)
characterized by a rapid weak pulse, low blood pressure, and in some
cases death (Rigau-Perez et al., 1998; Srikiatkhachorn et al., 2007).
The pathophysiology of dengue virus infection is host mediated
and not well understood. Secondary infections with a heterologous
serotype reportedly lead tomore severe disease that is suggested to be
the result of antibody dependent enhancement (ADE) (Halstead et al.,
1970). The ADEmodel postulates that non-neutralizing antibodies can
interact with the DENV and facilitate viral entry into monocytes and
macrophages via Fc receptors (Clyde et al., 2006; Green and Rothman,
2006). The excessive uptake of DENV leads to hyperactivation of Tcells
and an inappropriate immune reaction. The ADE response induces an
elevation of cytokines in the blood and results in vascular leakage
causing DHF or DSS.
Currently, there are signiﬁcant challenges associated with gen-
erating a successful vaccine for dengue virus. Since there are four
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to each serotype simultaneously to preclude the development of ADE
(Whitehead et al., 2007). The ability to generate a robust immunity to
four separate genotypes in a single vaccine would be a signiﬁcant
challenge. Thus, there is a great need to discover novel targets
involved in dengue viral infection to establish successful approaches
for treatment of the disease.
Cholesterol biosynthesis and transport has recently been identiﬁed
as an important modulator of the host response to several Flaviviridae
family viruses, including the Hepatitis C virus (HCV). Several statins
have been reported to inhibit HCV replicationwith ﬂuvastatin being the
most potent (IC50 of 0.9 μM) and lovastatin the weakest (IC50 of
2.16 μM) (Ikeda et al., 2006). Huh7 cells harboring a HCV replicon
express elevated levels of citrate lyase and acetyl-CoA synthetase genes,
both of which are involved in cholesterol and fatty acid biosynthesis. In
these cells, lovastatin's inhibition of the HCV replicon could be reversed
by geranylgeraniol but not farnesol addition (Kapadia and Chisari,
2005). Lovastatinwas also found to decrease viral load and increase CD4
counts inHIV-1-infected patients. The effect of lovastatin can be blocked
by mevalonate, and geranylgeraniol, but not by cholesterol or a farnesyl
transferase inhibitor (del Real et al., 2004).
The cholesterol pathway has also been shown to be important for
other Flavivirus including the West Nile virus, Japanese encephalitis
virus, and dengue virus infection (Lee et al., 2008; Mackenzie et al.,
2007; Medigeshi et al., 2008). Although the mechanism remains
unclear, the metabolism of cholesterol is necessary for Flavivirus entry
and replication, and the host's immune response to the virus (Lee et
al., 2008; Mackenzie et al., 2007; Medigeshi et al., 2008). To search for
the key cholesterol biosynthetic enzymes that regulate dengue virus
replication, we used siRNAs to selectively knock down enzymes
involved in key steps of cholesterol biosynthesis. siRNAs targeting
Mevalonate (diphospho) decarboxylase (MVD) were found to inhibit
dengue virus replication in a stable A549 subgenomic Renilla replicon
cell line (Rluc-replicon) and in naive A549 cells after dengue type 2
(DEN-2) New Guinea C (NGC) live virus infection.
MVD is an enzyme in the cholesterol biosynthesis pathway and has
beenshowntobeamemberof theGHMPkinase familywithactive sitesat
Asp 302 and Lys 18 (Krepkiy andMiziorko, 2004).MVD is responsible for
the production of isopentenyl 5-pyrophosphate from mevalonate 5-
pyrophosphate generating CO2 in the process. We found that siRNAs
targeting MVD could inhibit Rluc-replicon and DEN-2 NGC live virus
replication in K562 cells. In addition, the HMG-CoA synthase inhibitor
hymeglusin and squalene synthetase inhibitor zaragozic acid A could
signiﬁcantly inhibit DEN-2 NGC live virus replication in K562 cells, while
the geranylgeranyl transferase inhibitor (GGTI 2133) and farnesyl
transferase inhibitor (FTI III) were not effective. When the Rluc-replicon
cells were grown in delipidated media over time, Renilla luciferase
expression was inhibited indicating there was a need for exogenous
cholesterol to maintain replication. When cholesterol was added back to
the delipidated media (at 0.1 and 1µg/ml), viral replicationwas partially
restored. Taken together, our results suggest cholesterol metabolism is
required fordenguesubgenomicand full lengthviral replication inseveral
infected cell types.
Results
siRNA analysis of cholesterol biosynthetic genes
In an effort to identify genes in the cholesterol biosynthetic
pathway that play a critical role in the replication of the dengue virus,
we employed a candidate gene-by-gene approach using siRNA
mediated knock down. We selected enzymes expressed in A549
cells that are known to be essential for cholesterol biosynthesis
(Supplemental Table 1). SMARTpool siRNA transfection optimization
was performed in dengue subgenomic Renilla luciferase A549 replicon
cells (Rluc-replicon) as previously described (Borawski et al., 2007).Each SMARTpool was transfected for 72 h followed by analysis of
Renilla luciferase levels and cell viability, measured in parallel with
qRT-PCR (Figs. 1A–C). A previously validated siRNA targeting NS3 was
used as the positive control to inhibit viral replication while the
GAPDH SMARTpool was used as the negative control (Ng et al., 2007).
After a 72 hour transfection in the A549 Rluc-replicon cells,, the
control siRNA SMARTpool targeting GAPDH had no effect on Renilla
luciferase levels as compared to untransfected cells (data not shown)
while the NS3 siRNA inhibited Renilla luciferase N90% (Fig. 1A). The
GAPDH SMARTpool did not affect cell viability while the NS3 siRNA
reduced viability by 50%. Since the NS3 siRNA only inhibited cell
growth in the A549 Rluc-replicon cells, we think it is due to off target
effects of the siRNA on an unknown mRNA. From the collection of
siRNAs screened, siRNA SMARTpool targeting MVD knocked down
target mRNA levels by 80%, inhibited Renilla luciferase expression by
50%, while having no effect on cell viability. While most of the
SMARTpool siRNAs could knock down target mRNA levels (Fig. 1C),
the phenotypes associated with knock down were modest and/or
correlated with a decrease in cellular viability (Fig. 1B). Thus, only
MVD was pursued in follow up studies.
To further validate the role of MVD in viral replication, we analyzed
multiple independent siRNAs targeting MVD in the A549 Rluc-
replicon cells. Two of the four independent siRNAs from the SMART-
pool were found to inhibit replicon activity ∼3-fold with no effect on
cell viability (Figs. 2A, B). Both siRNAs signiﬁcantly inhibited MVD
protein levels as measured by Western blot (Fig. 2C). The two
validated siRNAs were also analyzed in naive A549 cells infected with
the DEN-2 NGC live virus using a plaque assay. The DEN-2 NGC live
virus was added to naive A549 cells 24 h after the siRNA transfection
with the validated MVD siRNAs (MVD-1, MVD-2), and the NS3 siRNA.
Both MVD-1 and MVD-2 siRNAs could inhibit DEN-2 NGC live virus
infection by 79% and 61%, respectively, as compared to the mock
transfected control (Fig. 3A). The MVD siRNAs caused no signiﬁcant
effect on cell viability (Fig. 3B). Thus, loss of MVD causes a reduction of
dengue viral replication in both the Rluc-replicon and DEN-2 NGC live
virus infected A549 cells.
Pharmacological inhibition of cholesterol biosynthesis
Another way to probe the activity of a pathway is to use
pharmacological tool compounds with deﬁned biochemical activities.
To determine if endogenous cholesterol production was important for
DEN-2 NGC live viral replication we analyzed several known
cholesterol inhibitors in dengue virus infected K562 cells, a hemato-
poetic cell line derived from human chronic myelogenous leukemia
cells. In Fig. 4A, the K562 cells were infected with DEN-2 NGC live
virus at a multiplicity of infection (MOI) of 1. An MOI of 1 was used
because higher MOIs caused a signiﬁcant drop in cell viability (data
not shown). We also analyzed the squalene synthetase inhibitor
zaragozic acid A (ZGA), which has been shown to inhibit cholesterol
biosynthesis and reduce hypercholesterolemia in vivo (Bergstrom et
al., 1993). After 48 h of DEN-2 NGC live virus infection, cells were
incubated with two antibodies, one against dengue envelope protein
(4G2) and the other against dengue NS1 protein. Treatment with
increasing concentrations of ZGA decreased the percentage of
envelope-NS1 double positive cells (gated cell population) from 5%
in the untreated population to 0.6% in the 10 μM treated population.
Due to the low level of infection (∼5%), subsequent experiments were
performed on the infected, virus positive cells. The inhibition of
infection by ZGA treatment was conﬁrmed by plaque assay (plaque
forming units (PFU)/ml) using the infected cell supernatants from the
infected cells (Fig. 4B). There was no signiﬁcant cytotoxicity observed
with the inhibitor in the infected cells as measured by CellTiter-Glo
(Fig. 4C).
Using the same method, we tested several other inhibitors of the
cholesterol biosynthesis pathway in K562 cells infected with DEN-2
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Fig. 2.Multiple independent siRNAs targeting MVD reduce dengue replication andMVD
protein levels in A549 cells. (A) A549 replicon cells were transfected with two
independent siRNA sequences targeting MVD (MVD-1, MVD-2) and GAPDH-sp for 72 h.
Renilla (A) and CellTiter-Glo (B) luciferase (expressed as relative light units RLUs) was
quantiﬁed. (C) Protein isolates from the siRNA transfected A549 replicon cells were
analyzed by Western blot using an anti-MVD and anti-actin antibody (loading control).
The Western blot is representative of three independent experiments.
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50% inhibition of virus growth as determined by plaque assay) and
CC50 (cytotoxicity at 50% cell death as determined by CellTiter-Glo) of
these inhibitors (Table 1). Only hymeglusin and ZGA signiﬁcantly
inhibited DEN-2 NGC live viral replication in K562 cells as measured
by plaque assay after FACS sorting. The therapeutic index (CC50/IC50)
of hymeglusin was 11 and 6 for ZGA. In contrast, the geranylgeranyl
transferase (GGTI 2133), farnesyl transferase (FTI III) inhibitors and
statins all had no effect on live virus replication.
We also analyzed a set of HMG-CoA reductase (HMGR) inhibitors
in the Rluc-replicon A549 cell line to pharmacologically verify that
inhibition of cholesterol production blocked subgenomic replication.
Both ZGA and hymeglusin had no effect on Renilla expression up to
50 μM after 48 h of treatment (data not shown). In contrast, four
statins, ﬂuvastatin, lovastatin, mevastatin, and simvastatin could
inhibit Renilla expression in the low micro molar range (b10 μM)
(Table 2). But the inhibition of Renilla levels also correlated with
inhibition of cell growth. The sensitivity of A549 cell growth to
statin treatment is not surprising as rapidly growing cancer cells are
known to be sensitive to HMGR inhibition (Bennis et al., 1993).
Since the therapeutic index (CC50/EC50) of ﬂuvastatin was ∼5 we
performed substrate rescue experiments in the presence of
ﬂuvastatin.
The Rluc-replicon A549 cells were treated with 0 μM, 5 μM or
20 μM ﬂuvastatin along with 100 μM mevalonate, 25 μM farnesyl
pyrophosphate (FPP), or 25 μMgeranylgeranyl pyrophosphate (GGPP)
for 72 h (Fig. 5). The mevalonate, FPP, and GGPP were dissolved in
ethanol and added to the cells at a ﬁnal concentration of 0.2% ethanol
(vehicle). DMSO was used to solubilize the ﬂuvastatin prior to
treatment. The ethanol vehicle and DMSO did not signiﬁcantly affect
Renilla luciferase levels or cellular viability (Figs. 5A–F, 0 μM vehicle
bars). The dose of ﬂuvastatin potently inhibited both Renilla luciferase
levels (Fig. 5A) and cellular viability (Fig. 5B). While treatment of
Rluc-replicon cells with mevalonate had no effect on Renilla luciferase
levels or cell growth, the presence of 100 μM mevalonate completely
reversed the cytotoxicity of ﬂuvastatin and restored replicon expres-
sion (Figs. 5A and B). Similar results were seen when 25 μM FPP (Figs.
5C and D) or 25 μMGGPP (Figs. 5E and F) was added to the ﬂuvastatin
treated cells, but the rescue of Renilla expression and cell viability was
not complete. While these lipid intermediates could rescue the
expression of the viral replicon, the rescue correlated with a rescue
of cellular viability. Thus a deﬁnitive therapeutic index was difﬁcult to
determine.
Statins are a safe and widely used class of drug for the treatment of
hypercholesterolemia (Itakura et al., 2008). The cytotoxicity that we
observed in A549 cells was similar to statin cytotoxicity reported in
other cancer cell lines in culture (Bennis et al., 1993; Maksimova et al.,
2008). To avoid statin induced toxicity found in transformed cell lines,
we collected healthy donor PBMCs and tested the effect of lovastatin
treatment on DEN-2 NGC live virus replication in these cells. PBMCs
were infected with a clinically isolated dengue strain, MY10340, for
48 h in the presence of enhancing antibodies from dengue positive
plasma. The infectionwas assessed by FACS, the cells were sorted, and
the plaque assay was performed. As shown in Fig. 6, both the
percentage of infected cells and the virus titer decreased with
increasing concentration of lovastatin while cytotoxicity was not
observed. Since PBMCs are a physiologically relevant model system to
study the dengue virus life cycle, lovastatin's inhibtion of dengue
replication in the absence of cellular toxicity is an important
observation.Fig. 1. siRNA mediated knock down of cholesterol biosynthetic genes in dengue replicon cells
Renilla luciferase (A) and CellTiter-Glo luciferase (B) was analyzed (expressed as relative l
experiments and the error bars represent calculated standard deviations. (B) mRNA levels
represents independent mRNA isolates from three siRNA transfections. The data were norm
transfected cells. mRNA knock down was expressed relative to GAPDH control expression (Endogenous cholesterol mobilization after dengue infection
It has been reported that cholesterol levels are regulated and
enriched in the plasma membrane while cholesterol is less abundant
in the endoplasmic reticulum (Jingami et al., 1987). We found that the
levels of total cellular cholesterol did not change in the A549 DEN-2
NGC live virus infected cells (data not shown). From this observation
we predicted it was possible a local change in the intracellular
cholesterol pools at the endoplasmic reticulum, the site of the viral
replication complex, could be altered by viral infection. To detect if
intracellular cholesterol pools were concentrating in the endoplasmic
reticulum after infection, we measured mRNA levels of HMG-CoA
reductase (HMGR) and low density lipoprotein receptor (LDLR). Both. (A) A549 Dengue replicon cells were transfected with SMARTpool siRNAs for 72 h and
ight units, RLU). Each bar represents three independent replicates from two separate
were quantiﬁed in the siRNA transfected A549 replicon cells using qRT-PCR. Each bar
alized to the internal control actin and divided by normalized data from GAPDH siRNA
error bars represent the standard deviation of triplicate results).
Fig. 3.MVD siRNAs reduce DEN-2 NGC live virus infection in naïve A549 cells. (A) A549
cells were infected with 1 MOI of NGC virus for 48 h after the transfection of the
validated siRNAs (MVD-1, MVD-2) as well as the control NS3 siRNA. Virus titer was
determined by plaque assay and normalized to that of mock transfected cells (B) Cell
viability was determined after the siRNA transfection and DEN-2 NGC live virus
infection using CellTiter-Glo (expressed as luciferase relative light units (RLUs)) (error
bars represent the standard deviation of triplicate results).
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cholesterol in the endoplasmic reticulum by the cholesterol sensing
complex of SREBP (Sterol regulatory element binding protein)-SCAP
(SREBP cleavage activating protein), which activates HMGR and LDLR
expression when endoplasmic reticulum cholesterol levels are low
(Vallett et al., 1996; Goldstein et al., 2006). Since the endoplasmic
reticulum is the site of replication for the virus, we measured mRNA
levels of HMGR and LDLR as a surrogate measure for endoplasmic
reticulum cholesterol levels. As shown in Figs. 7A and B, after
normalizing the expression levels to GAPDH, the transcript level of
HMGR and LDLR remained unchanged in the uninfected cells over a
72 hour time period, while the levels of both genes decreased
signiﬁcantly starting at 48 h after infection. The suppression of HMGR
and LDLR mRNA levels indirectly suggests there is an increase in
cholesterol content in the endoplasmic reticulum after viral infection.
Since the overall levels of cholesterol are not changing, dengue viral
infection is likely altering the intracellular distribution of cholesterol
in the cell.
To further elucidate the requirement of cholesterol for dengue
replication, we grew A549 Rluc-replicon cells in delipidated depleted
media for 72 h measuring both cell viability and replicon expression.
Although the replication activity correlated with growth in complete
media, the cells grown in delipidated media had only 50% of the Re-
nilla luciferase levels remaining (Fig. 8A). The cells went through two
doublings in three days and grew at the same rate in complete or
delipidated media in both wild type (data not shown) and dengue
subgenomic replicon cells (Fig. 8B). Thus, exogenous cholesterol levelsplay an active role in maintaining replicon expression in the stable
subgenomic cell line where virus entry or egress is not occurring.
If exogenous cholesterol levels are essential to maintain active
replication of the subgenomic virus, then addition of cholesterol to the
delipidated media should rescue Renilla luciferase expression. To test
this possibility we added 0, 0.1, 1.0, and 10 μg/ml of cholesterol to the
delipidated media and monitored Renilla luciferase expression in the
A549 replicon cells over a 72 h period. We found that 10 μg/ml
cholesterol added to the complete and delipidated media resulted in a
drop in Renilla luciferase levels (Figs. 8E and F) and caused the cells to
stop growing in both complete (Fig. 8D) and delipidated media
(Fig. 8F). When 0.1 or 1.0 μg/ml of cholesterol was added to back to
complete media there was a small increase in Renilla expression and
cellular viability (Figs. 8C, D). As well, the addition of 0.1 or 1.0 μg/ml
of cholesterol partially restored Renilla expression in the delipidated
media as compared to no cholesterol treatment (Fig. 8E). There was
also a slight increase in the growth of the cells after treatment of 0.1 or
1.0 μg/ml of cholesterol to the delipidated media (Fig. 8F). We also
treated the Rluc-replicon cells growing in delipidated media with
100 μM mevalonolactone, 25 μM geranylgeranyl pyrophosphate and
farnesyl pyrophosphate and found no effect on Renilla luciferase levels
(data not shown). Of the lipids we added back to the delipidated
media, only a low dose of cholesterol (0.1 and 1.0 μg/ml) could restore
Renilla expression in the Rluc-replicon cells along with cell growth.
Discussion
We have demonstrated dengue virus replication can be altered
when endogenous cholesterol production or exogenous cholesterol
uptake is modulated. After screening a collection of siRNAs targeting
key nodes of the cholesterol biosynthetic pathway, we found that
knock down of MVD could inhibit dengue viral replication (Figs. 1–3).
Although the cholesterol pathway has been previously identiﬁed as
important for dengue virus uptake and replication, there are no
speciﬁc reports identifying a requirement for MVD.
Knock down of MVD would be predicted to inhibit endogenous
cholesterol production as well as increase mevalonic acid levels in the
cell. But the effects of mevalonic acid on dengue viral replicon are still
unknown. It has been shown dengue replication depends on the
production of endogenous cholesterol because viral proteins require
lipid rafts to replicate and trafﬁc efﬁciently in the cell (Lee et al., 2008).
But our data demonstrate MVD knock down is sufﬁcient to reduce
Rluc-replicon and DEN-2 NGC live virus replication. Since MVD knock
down cannot be rescued by cholesterol, FPP, GGPP, or mevalonate
(Supplemental Fig. 1) suggests other pathways besides cholesterol
production, are involved. Such pathways could include cholesterol
localization and viral protein post-translational modiﬁcation and/or
trafﬁcking in the cell.
All of the validated siRNAs could knock down their target mRNA
levels in the Rluc-replicon cells but only siRNAs targeting MVD could
inhibit Renilla luciferase levels with minimal effect on cell viability.
There are several explanations for the lack of a phenotype with the
other siRNAs. First, not all enzymes in the cholesterol biosynthesis
pathway, and/or the products they metabolize, are rate limiting for
cholesterol production. Therefore their inhibition might not be
sufﬁcient to alter intracellular cholesterol distribution (Bengoechea-
Alonso and Ericsson, 2007). Second, since we did not measure protein
knock down for every gene in the pathway, it could be that mRNA
knock down did not translate into protein knock down for every gene
we tested. Several enzymes in the cholesterol biosynthesis pathway
are known to have slow rates of turnover in the cell (Bengoechea-
Alonso and Ericsson, 2007). It is also possible that even a small
amount of residual enzyme is sufﬁcient to keep the pathway fully
functional. As we found with knocking down MVD, the ability to
achieve complete ablation of protein levels was difﬁcult to achieve
(Fig. 2). Several siRNAs caused an inhibition of cell growth, which also
Fig. 4. The squalene synthesis inhibitor zaragozic acid A (ZGA) inhibits DEN-2 NGC live virus infection in K562 cells. (A) FACS analysis of K562 cells infectedwith DEN-2 NGC live virus
and treated with a dose range of ZGA for 48 h. Cells were labeled with an anti-E antibody (4G2-AlexaFluor 680) and an anti-NS1 antibody (NS1-AlexFluor 688) before FACS. Dengue
positive cells (in the upper right corner) constituted 4.8% of the total cell population. After ZGA treatment, the percent positive cells dropped from 4.8% to 2.8% with 0.1 μM ZGA and
0.6%with 10 μMZGA. (B) The FACS results were conﬁrmed by plaque analysis after 48 h of ZGA treatment in the infected and sorted K562 cells. (C) ZGA treatment had no effect on cell
viability as measured by CellTiter-Glo. Each FACS plot and bar graph is a representative of three independent experiments.
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on-target and off target effects of the siRNAs.
Our siRNA experiments were performed in the presence of 10%
serum (with the exception of the delipidation media using MVD
siRNAs, Supplemental Fig. 1), which contains cholesterol. If the media
is saturating for cholesterol in 10% serum, then the cell can actively take
up cholesterol even if the endogenous cholesterol biosynthesis
pathway is inhibited. Although MVD knock down inhibits dengue
replication ∼2-fold, it is likely that competing stores of cholesterol in
the cell (or excess cholesterol in the media) prevents complete
inhibition of the pathway in cell culture. As well, cholesterol could be
redistributed in the cells even in cases where endogenous production
is inhibited. Our delipidation results (Fig. 8A) suggest exogenous
cholesterol is necessary for replication while uptake and intracellularTable 1
Pharmacological inhibitors of DEN-2 NGC live virus infection in K562 cells.
Class Compound EC50a CC50b
HMGCoA reductase inhibitor Fluvastatin N50 μM 48.8 μM
HMGCoA reductase inhibitor Lovastatin N50 μM 46.8 μM
HMGCoA synthase inhibitor Hymeglusin 4.5 μM 50 μM
Squalene synthetase inhibitor Zaragozic acid A 8.3 μM N50 μM
Farnesyl transferase inhibitor FTI III N50 μM N50 μM
Geranylegeranyl transferase inhibitor GGTI 2133 N50 μM N50 μM
aEC50 (concentration of 50% inhibition of virus growth as measured by plaque assay)
and bCC50 (concentration at 50% cell death as measured by CellTiter-Glo) were
calculated after a 48 h eight point dose response compound treatment in dengue type 2
NGC live virus K562 infected cells.distribution of cholesterol can be alteredbyviral infection (Figs. 7A and
B). The depletion of MVD could also prevent exogenous cholesterol
from getting to the site of dengue viral replication.
MVD catalyzes the decarboxylation of mevalonic acid pyropho-
sphate to form isopentenylpyrophosphate, a key intermediate in the
cholesterol cascade. AlthoughMVD is not the rate limiting reaction for
cholesterol production, the phosphorylated intermediates may serve
regulatory functions in lipid biosynthesis, including a reduction of
cholesterol from acetate. In addition, the inhibition of MVD can lead to
an increase in mevalonic acid pyrophosphate linked to the regulation
of fatty acid synthetic enzymes (Ku, 1996). There are known genetic
mutations in the MVD pathway associated with loss of the kinase
activity of the MVD phosphorylating enzyme MVK (Cuisset et al.,
2001). Thus, the inhibition of MVD in the dengue replicon cells could
result in not only a reduction of cellular cholesterol levels, but also theTable 2
Pharmacological inhibitors of dengue subgenomic replicon in A549 cells.
Class Compound EC50a CC50b
HMGCoA reductase inhibitor Fluvastatin 1.82 μM 8.97 μM
HMGCoA reductase inhibitor Lovastatin 6.20 μM 12.03 μM
HMGCoA reductase inhibitor Mevastatin 8.75 μM 11.75 μM
HMGCoA reductase inhibitor Simvastatin 4.83 μM 8.43 μM
HMGCoA reductase inhibitor Pravastatin 46.33 μM 50.00 μM
HMGCoA reductase inhibitor Rosuvastatin 39.45 μM 46.50 μM
aEC50 (concentration of 50% inhibition of virus growth) and bCC50 (concentration at
50% cell death) were calculated after a 48 h eight point dose response compound
treatment in dengue subgenomic replicon in A549 cells.
Fig. 5. Fluvastatin inhibitionof dengue replicationand cell viability canbe reversedwithmevalonate, geranylgeranyl pyrophosphate (GGPP), and farnesyl pyrophosphate (FPP). (A)Dengue
A549 subgenomic replicon cells were treated for 72 hwith 5 μMor 20 μM ﬂuvastatin in the presence of 100 μMmevalonate (A, B), 25 μMFPP (C, D), or 25 μMGGPP (E, F). Ethanol was the
vehicle used to solubilize the lipids and was added to the cells at a ﬁnal concentration of 0.2%. Renilla luciferase (A, C, E) and CellTiter-Glo (B, D, F) were quantiﬁed at 72 h.
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pyrophospho-mevalonic acid. The manner in which intermediates in
the cholesterol biosynthesis pathway may modulate dengue replica-
tion requires further study.
It is possible intermediates of acetoacetyl-CoA metabolism could
be important regulatory molecules that inﬂuence dengue protein
modiﬁcation. The contribution of metabolites from acetoacetyl-CoA
metabolism on dengue viral replication will require additional
analysis. Statin therapy is known to prevent geranylation of small G-
proteins and suppress inﬂammatory signals initiated from the plasma
membrane (Ky and Rader, 2005; Houten et al., 2003). Since severe
cases of DHH and DSS result from an inappropriate inﬂammatory
response, the anti-inﬂammatory effects of statins on dengue infection
should be explored further.In order to understand the requirement of cholesterol in dengue
viral replication, we tested whether dengue viral infection could
induce changes in intracellular cholesterol distribution using mRNA
levels of HMGR and LDLR as surrogate markers for endoplasmic
reticulum cholesterol levels. Although we did not identify a signiﬁcant
change in the total cholesterol content of the cell after DEN-2 NGC live
virus infection in A549 cells (data not shown), we found that the
mRNA levels of HMGR and LDLR were decreased after dengue live
virus infection (Fig. 7). Under conditions of low cholesterol in the
endoplasmic reticulum, the cholesterol sensor SREBP (Sterol regula-
tory element binding protein)-SCAP (SREBP cleavage activating
protein) complex is transported to the Golgi compartment where
S1P/S2P proteases can cleave the cytoplasmic domain of SREBP to
allow it to translocate into the nucleus and act as a transcription factor
Fig. 6. Lovastatin inhibits DEN-2 NGC live virus infection in human PBMCs. (A) Isolated
human PBMCs were infected with DEN-2 NGC live virus and treated with a dose range
of lovastatin for 48 h. The percentage of anti-E (4G2) and NS1 double positive cells were
identiﬁed by FACS analysis (as in Fig. 4) and expressed as a bar graph with increasing
concentrations of lovastatin. (B) Live virus titer in PBMCs was determined by plaque
assay after infection and lovastatin treatment. (C) Cell viability was determined using
CellTiter-Glo in PBMCs infected with virus and treated with lovastatin for 48 h. The bar
graphs are representative of three independent experiments and standard deviations
were calculated.
Fig. 7.HMG-CoA reductase (HMGR) and low density lipoprotein receptor (LDLR) mRNA
levels are reduced after live DEN-2 NGC live virus infection in A549 cells. (A, B) mRNA
levels for HMGR (A) and LDLR (B) were quantiﬁed by qRT-PCR in uninfected A549 cells
(black bars) and A549 cells infected (open bars) with 1 MOI of NGC virus for 24 h, 48 h,
and 72 h. Values were normalized to the internal control GAPDH and expressed as
relative fold change to GAPDH mRNA levels. Each bar represents three independent
wells, infected or uninfected (error bars represent the standard deviation of triplicate
results).
15C. Rothwell et al. / Virology 389 (2009) 8–19to induce HMGR and LDLR gene transcription (Vallett et al., 1996).
Since it was observed that infection suppressed the transcript level of
both HMGR and LDLR, it indirectly indicates that cholesterol was
present in the endoplasmic reticulum, which is the primary site of
dengue virus replication (Perera and Kuhn, 2008). It has been
reported that West Nile infection caused a relocalization of plasma
membrane cholesterol to the viral replication site and that HMGR was
found to co-localize with viral proteins (Mackenzie et al., 2007). It has
also been shown that the dengue replication complex is located in
intracellular cholesterol rich micro domains (Lee et al., 2008). As
cholesterol rich micro domains are known to reside in the endoplas-
mic reticulum, it is possible they are present at the site of the dengue
replication complex. Our data support the model that DEN-2 NGC live
virus infection induces a shift in intracellular cholesterol levels.
To conﬁrm that exogenous cholesterol was necessary for dengue
virus replication, we grew the stable replicon cells in delipidated
media for 72 h (Fig. 8). Although all the cells grew normally in
delipidated media, the replication of the virus was inhibited by 2-fold.
The cells were “shocked” by transfer from complete media intodelipidated media so that the endogenous stores of cholesterol would
be replete at the time of the assay. It was surprising that stable viral
replication was inhibited as early as 72 h, suggesting the demand for
exogenous cholesterol was signiﬁcant. Our data are consistent with
the ﬁndings of Lee et al. who demonstrated exogenous cholesterol
chelation could reduce intracellular replication of Japanese encepha-
litis and the dengue type 2 viruses (Lee et al., 2008). Cholesterol
addition to the delipidated media was not able to restore dengue
replication independent of effects on cell growth (Figs. 8C–F). There
was also a clear dose dependent inhibitory effect on cell viability in the
A549 Rluc-replicon cells at 10 μg/ml cholesterol (Figs. 8C–F). Since the
intermediates mevalonate, FPP, and GGPP could also not rescue
replication in delipidated media (data not shown), it is still not clear
exactly what factors absent in the delipidated media are necessary for
replicon expression.
Cholesterol pools are dynamic and in a constant state of ﬂux
between membranes and biosynthetic pathways. It is not yet clear
whether dengue infection increases the demand for cholesterol to
regulate membrane ﬂexibility or stabilize the viral replication
complex. Protein farnesylation and geranylation do not seem to play
a role in regulating viral replication since these compounds targeting
these enzymes have no obvious effects on dengue virus replication
(Table 1). We have not ruled out other downstream metabolites of
Fig. 8. Endogenous cholesterol depletion prevents dengue viral replication over time. A549 dengue subgenomic replicon cells were grown over a 72 h time period in complete (ﬁlled
triangles) or delipidated (open triangles) media. (A) Renilla luciferase and CellTiter-Glo (B) were quantiﬁed every 24 h. (C, D) A549 dengue subgenomic replicon cells were grown
over a 72 h time period in complete media supplemented with cholesterol at 0 μg/ml (ﬁlled triangles), 10 μg/ml (ﬁlled square), 1 μg/ml (ﬁlled diamond), or 0.1 μg/ml (ﬁlled circle).
Renilla luciferase (C) and CellTiter-Glo (D) were quantiﬁed every 24 h. (E, F) A549 dengue subgenomic replicon cells were grown over a 72 h time period in delipidated media
supplemented with cholesterol at 0 μg/ml (open triangles), 10 μg/ml (open square), 1 μg/ml (open diamond), or 0.1 μg/ml (open circle). Renilla luciferase (E) and CellTiter-Glo (F)
were quantiﬁed every 24 h. Each point represents replicates of three from three independent experiments (error bars represent the standard deviation of triplicate results).
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metabolites as regulators of viral replication.
We used pharmacological tool compounds to validate the hypoth-
esis that dengue replication requires active cholesterol production.
There are a number of cholesterol biosynthetic inhibitors including
statins, squalene synthesis inhibitors, geranylgeranylation inhibitors,
and farnesylation inhibitors, all of which are known to inhibit
cholesterol production. Interestingly, the HMG-CoA synthase inhibitor
hymeglusin and the squalene synthetase inhibitor zaragozic acid A
could inhibit DEN-2 NGC live virus infection in the low micromolar
range (Table 1, Fig. 4) while the geranylgeranylation inhibitors and
farnesylation inhibitors had no effect. Our data suggest that the sterol
branch of cholesterol metabolism including squalene production is
necessary for dengue viral replication. Although ﬂuvastatin was the
most potent statin we tested in A549 cells, it signiﬁcantly inhibited
cell growth making the interpretation of the rescue data difﬁcult
(Table 2 and Fig. 5). Another possible concern with substrate rescue
experiments is the inability to control for how much of the lipid
intermediate actually gets to its appropriate site in the cell. It is clear
that these tumor cells are not optimal for the study of dengue virus
replication and more relevant model systems are needed.
One of the challenges associated with studying the dengue virus in
cancer cell lines derived from tissues is that the dengue virus primarily
infects blood cell lines. The innate properties of immortalized tumor
cells are distinct from blood cells and normal tissues. The low rates of
infectivity in K562 and A549 cells makes population based viralreplication studies in the absence of FACS sorting difﬁcult. In addition,
the use of statins and other pharmacological agents in K562 and A549
cells was confounded by inhibitory effects on cell growth and viability.
An explanation of why the pharmacological agents were cytotoxic was
due to their low cellular efﬁcacy. Most of these compounds are known
to be nanomolar enzyme inhibitors, while we observed cellular
activity in the low micromolar range (Tables 1 and 2). It could be at
these high doses the compounds are having off target effects in the cell
and inhibit cell growth as a result.
One way we could overcome the cytotoxicity was use a more
relevant physiological model system, to infect donor PBMCs and treat
with lovastatin (Fig. 6). In this model system, we found both potent
inhibition of dengue viral replication and no effect on cellular viability.
While the tumor cell lines are growth inhibited by small molecule
cholesterol metabolism inhibitors, the inhibition of DEN-2 NGC live
virus replication in PBMCs suggests statins should be explored as a
modulator of dengue virus infection and/or replication. The PBMCs
are also advantageous to study dengue viral replication since they are
not a transformed tumor cell line.
In conclusion, the mechanism of action of cholesterol in dengue
viral replication requires more study. Our results demonstrate that
pharmacological inhibition of the cholesterol pathway using small
molecular weight compounds or siRNAs is a viable approach to inhibit
dengue virus replication (Fig. 9). We have shown that dengue
infection requires both endogenous and exogenous routes of choles-
terol acquisition to maintain viral replication. The question remains as
Fig. 9.Disruption of host cholesterol biosynthesis through the sterol arm inhibits dengue viral replication. Pharmacological intervention using statins, hymeglusin, or zaragozic acid A
can potently inhibit DEN-2 NGC live virus infection in K562, A549, and human PBMCs. Inhibition of farnesylation or geranylgeranylation has no effect on dengue replication
suggesting the non-sterol branch of cholesterol biosynthesis does not seem to play a role in dengue viral replication. In addition, genetic evidence suggests MVD knock down inhibits
both DEN-2 NGC live virus production (Fig. 3) and replicon Renilla luciferase (Figs. 1–2) in A549 cells.
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titers in an animal model, and ultimately, in humans. As other studies
have also shown that cholesterol is essential for dengue viral
replication and the host immune response to West Nile virus
infection, Flaviviridae viral infections seem to be modulated by host
cholesterol metabolism (Mackenzie et al., 2007). It seems a retro-
spective epidemiological study of dengue infection rates and severity
of dengue fever of patients on statin therapy would be warranted. The
genetic evidence that knock down of MVD can inhibit both a
subgenomic replicon and dengue live virus infection suggests MVD
could be a novel target in the cholesterol biosynthesis pathway for
which small molecule therapies could be developed.
Materials and methods
Cells lines and dengue virus
The human lung-epithelial carcinoma A549 cell line and hemato-
poetic K562 cell line were obtained from the American Type Culture
Collection (ATCC). PBMCs (Peripheral Blood Mononuclear Cells) wereprepared from buffy coat from health donors using ﬁcoll gradient. The
DENrepPAC2A-Rluc construct was derived from a DEN-2 NGC
infectious clone pDVWS601. pDVWS601 is a non-infectious, self
replicating dengue virus with a Renilla luciferase reporter under
puromycin selection, as previously described (Gualano et al., 1998; Ng
et al., 2007). A549 cells were cultured in F-12 (Hams) medium
(Invitrogen, Carlsbad, CA), supplemented with 10% fetal bovine serum
(FBS) and puromycin (10–50 μg/ml). Dengue New Guinea C (NGC)
virus (GenBankM29095) and the Malaysian clinical isolates MY10340
(from Shamala Devi, University of Malaya, Malaysia) were propagated
in insect cells C6/36 (ATCC). For virus titer analysis, the level of live
virus was determined by plaque assay in BHK-21 cells (ATCC) in
triplicate. For the delipidation growth curves, 6000 cells per well were
cultured either in complete mediumwith 2% FBS or in media with 4%
delipidated FBS. Heat inactivated FBS was delipidated with addition of
3.3 mg/ml fumed silica (Sigma, St. Louis, MO) for 4 h at room
temperature. The mixture was centrifuged (2000 ×g for 20 min) and
passed through a 0.2 μM ﬁlter before freezing as aliquots. The 2% FBS
serum from the same lot was treated identically with the exception of
silica addition.Water soluble cholesterol (Sigma) was added at time 0,
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EnduRen and CellTiter-Glo (CTG) luminescent assays (Promega,
Madison, WI).
siRNA transfections
All siRNAs were ordered from Dharmacon and listed in Supple-
mentary Table 1 (Dharmacon, Lafayette, CO). The NS3 siRNAs was
designed in-house, (DQ193572, GAUGGAGCCUAUAGAAUCAUU) as
previously described (Ng et al., 2007). The GAPDH siRNA was used
as the negative control in these studies because it was found to have
similar results to the scrambled control (data not shown). Each siRNA
was resuspended in siRNA buffer to a stock concentration of 20 μM.
The 2.5 μl of each stock solutionwas diluted in 197.5 μl of OPTI-MEM 1
(Invitrogen, Carlsbad, CA) in a 96 well PCR plate to make a working
10×stamp of 250 nM. For the lipid reagent 0.28 μl of Oligofectamine
(Invitrogen, Carlsbad, CA) was diluted in 10 μl and added stamped in a
96 well PCR plate. The 10 μl solution of siRNA and 10 μl of lipid was
transferred to a 96 well tissue culture plate and incubated for 20 min
at room temperature. After the incubation, 6000 A549 cells in 80 μl of
assay medium were plated on the siRNA:lipid reagent complex using
the Multidrop384 liquid handler (Thermo, Waltham, MA). For
cholesterol rescue experiments, 48 h after siRNA transfections water
soluble cholesterol (Sigma) at 1 μg/ml, mevalonolactone (Sigma)
100 μM, geranylgeranyl pyrophosphate (GGPP; Sigma) 25 μM, and
farnesyl pyrophosphate (FPP; Sigma) 25 μM, was added for an
additional 48 h. The mevalonolactone was dissolved in DMSO while
GGPP and FPPwere dissolved in 100% ethanol. Stocks were diluted and
added to cells at a ﬁnal concentration of 0.1% DMSO and 0.2% ethanol
(vehicles). Cells were assayed at 72 h using EnduRen and CellTiter-Glo
(CTG) luminescent assays (Promega, Madison, WI).
Real-time PCR
Three wells were transfected with siRNAs and mRNA was
isolated after 72 h using the TurboCature 96 kits (Qiagen, Valencia,
CA). Each cDNA was generated using high capacity cDNA reverse
transcriptase kit (Applied Biosystems, Foster city, CA). Three
separate transfections were assayed separately to eliminate inter-
assay differences. For the qRT-PCR a reaction mix containing 4.2 μl
diluted cDNA, 6 μl 2×PCR buffer (Applied Biosystems, Foster City,
CA), 0.6 μl GOI probe labeled with FAM/MGH and 0.6 μl of β-Actin
probe labeled with VIC/TAMRA was set up in 384 well plates. The
mRNA levels were measured using an Applied Biosystems 7900HT
using gene speciﬁc primers from Applied Biosystems as listed in
Supplementary Table 1.
For HMGR and LDLR real-time PCR, total RNAwere extracted using
Rneasy kit (Qiagen, Valencia, CA). One-step RT-PCR Syber Green kit
(Biorad, Hercules, CA) using HMGR, LDLR and GAPDH speciﬁc 5′ and
3′ primers (HMG-CoAR 5′ primer: GACGCAACCTTTATATCCGTTT, 3′
primer: TTTTGAAAGTGCTTTCTCTGTACC; LDLR 5′ primer: GATGT-
CAATGGGGGCAAC, 3′ primer: TCGTTGATGATATCTGTCCAAAAT;
GAPDH 5′primer: CTCTGCTCCTCCTGTTCGAC, GAPDH 3′ primer:
ACGACCAAATCCGTTGACTC) according to the Biorad protocol. The
15 μl reaction was loaded in a 96 well plate and run with a Biorad iQ5
machine using the manufactures protocol.
EnduRen live cell assay
Sixty millimolar EnduRen stocks were diluted 1:100 into pre-
warmed assay medium and 1:10 dilutions were made by adding
10 μl of diluted EnduRen to each well of a 96-well plate containing
100 μl of cells, for a ﬁnal concentration of 60 μM. Cells were pulsed
for 2 h with 60 μM EnduRen and luminescence was measured after
10 min using an EnVision 2100 multilabel reader (PerkinElmer,
Waltham, MA).Low molecular weight inhibitors
Statins were run in A549 Dengue replicon assays by plating at 6000
cells per well in 96 well plates. The following day two-fold serial
dilutions of the compounds were prepared in assay medium and
stamped out in a 96well plates. A 12 point dose curve of a 1:1 dilution,
starting at 50 μM, was plated followed by EnduRen and CellTiter-Glo
assays at 72 h. Samples were run in triplicate, averaged, and standard
deviations were calculated. All of the statins and zaragozic acid A
(ZGA) stocks were purchased from Sigma. For rescue experiments,
cholesterol pathway intermediates: mevalonolactone (Sigma)
100 μM, geranylgeranyl pyrophosphate (GGPP; Sigma) 25 μM, and
farnesyl pyrophosphate (FPP; Sigma) 25 μM were added to the cells
followed by compound addition. Samples were assayed using
EnduRen and CTG luminescent assays 72 h after compound addition.
Western blot analysis
For Western blot analysis, cells were cultured in 6 well plates at
200,000 cells per well and treated with compound or siRNA as
described. Brieﬂy 200 μl Oligofectamine in Opti-MEM and 200 μl
siRNAwere preincubated for 20 min on the plates, cells were added to
the plate in 1 ml of assay medium, a further 400 μl of medium was
added and the cells incubated overnight. The following day 200 μl of
10×compound was added in 200 μl assay medium. After 72 h the
mediumwas removed and wells were washed twicewith ice cold PBS.
Cells were lysed in 300 μl ice cold lysis buffer (made up of 10 ml RIPA
(Boston Bioproducts, Worcester, MA) plus protease inhibitor tablet
(Roche, Basel, Switzerland)) while rocking on ice for 20 min. Protein
concentration was determined by BCA assay (Pierce, Rockford, IL).
Samples were boiled in Laemli buffer, cooled, and loaded onto a 4–12%
Tris–glycine pre-cast gel using 8–10 μg of total protein (Invitrogen,
Carlsbad, CA). Proteins were separated using 1×Tris–glycine SDS
running buffer (Bio-Rad, Hercules, CA) at 120 V for 1.5 h. Proteins were
transferred to nitrocellulose using the tank transfer method in
1×Tris–glycine transfer buffer (Bio-Rad, Hercules, CA) at 100 V for
1.5 h at 4 °C. The blots were blocked in blocking buffer (1×PBS, 5% w/
v blotting grade blocker nonfat dry milk (Bio-Rad, Hercules, CA))
overnight at 4 °C. The membranes were probed with either 1 μg/ml
anti-MVD clone 2A7 (Afﬁnity BioReagents, Golden, CO), 1:5000 anti-
actin clone AC-15, and 1:5000 anti-mouse horseradish peroxidase
(HRP) secondary antibody (Sigma, St. Louis, MO). All incubationswere
incubated in blocking buffer for 1 h at room temp followed by three
washes. SuperSignal chemiluminescent substrate kit (Pierce, Rock-
ford, IL) and Kodak's X-Omat AR-2 ﬁlm were used.
Infectious virus assay and FACS
For siRNA testing, the individual MVD siRNA duplexes were
transfected in 96 well plates and DEN-2 NGC virus was added at 1
multiplicity of infection (MOI) for 48 h. The MOI was optimized at 1
because higher MOIs were found to be toxic to the cells (data not
shown). The virus titers were determined using a plaque assay as
previously described (Fink et al., 2007). For compound testing,
50,000 K562 cells were aliquoted in 96 well plates at 100 μl and
infected for 24 h with 1 MOI of DEN-2 NGC virus and incubated for
additional 48 h. Compounds were added together with the virus
and the viral growth was measured by FACS using two antibodies,
the anti-dengue envelope protein antibody conjugated to Alexa 680
and the anti-NS1 antibody conjugated to Alexa 488 as previously
described (Pupo-Antúnez et al., 1997). The same protocol was used
for the PBMC infections except that 500,000 cells were plated in a
1:10,000 diluted dengue IgG positive serum to enhance virus uptake
into the cells.
To determine the EC50 (concentration of 50% inhibition of virus
growth) and CC50 (concentration at 50% cell death) a dose response
19C. Rothwell et al. / Virology 389 (2009) 8–19of compound was added to the K562 cell infections. The decrease of
the percentage of the dengue positive cells was plotted against the
concentrations of inhibitors using a nonlinear regression analysis to
obtain the EC50 (Sigma Plot 9.0). The CC50 was calculated using the
same method to determine cell viability over the range of inhibitor
concentrations used.
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